Ascendis Pharma A/S financial data

Symbol
ASND on Nasdaq
Location
Hellerup
Fiscal year end
31 December
Latest financial report
20-F - Q4 2025 - 11 Feb 2026

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 61,977,408 shares 2.1%

Income Statement

Label TTM Value / Value Unit Change %
Research And Development Expense €303,621,000 EUR -1.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Assets €1,302,570,000 EUR 10%
Liabilities €1,465,391,000 EUR 14%